Mark Treherne

Mark Treherne is an experienced executive in the life sciences sector. Mark has held various roles in multiple companies since 2008. In 2021, they were appointed Chairperson of Monument Therapeutics, where they are responsible for developing therapeutic products to treat serious diseases of the central nervous system. From 2018 to 2021, they were the Chief Executive of Cellesce Ltd, a Life Sciences company that developed a patented bioprocessing technology for the growing and expansion of organoids. From 2016 to 2018, they were the Chief Executive of Avilex Pharma ApS, a spin out from the University of Copenhagen. From 2015 to 2018, they were a Non-Executive Director at Cell Guidance Systems and from 2013 to 2018, they were the Chairperson of Talisman Therapeutics Limited and Ubiquigent Limited. From 2012 to 2016, they were the Chief Executive of the UK Trade and Investment Life Sciences Organisation. From 2008 to 2013, they were a Consultant and then Chairperson of CYCLOFLUIDIC LIMITED and a Non-Executive Director of Domain Therapeutics.

Mark Treherne obtained their B.Sc. in Physiology and Pharmacology from the University of St Andrews in 1983. Mark then went on to receive their M.Phil. in Pharmacology from the University of Cambridge in 1984. Finally, they completed their Ph.D. in Pharmacology from the University of Cambridge in 1987.